

# PMedIC Seminar Series

## Clinical Proteogenomic Tumor Analysis Consortium

Wednesday, September 8, 2021

3:00 p.m. – 4:00 p.m. P.T.

[MS Teams meeting link](#)



**Dr. Karin Rodland**

*Laboratory Fellow, Biological Sciences Division,  
Pacific Northwest National Laboratory  
Professor Emeritus, Developmental & Cancer  
Biology, School of Medicine  
Oregon Health & Science University*



**Dr. Jeffrey Tyner**

*Professor, Cell, Developmental, and Cancer  
Biology,  
Oregon Health & Science University*

The Clinical Proteogenomic Tumor Analysis Consortium is focused on the application of cutting-edge mass spectrometry capabilities to compelling problems in cancer biology, and the OHSU-PNNL collaboration to form a Proteogenomic Translational Research Center for Acute Myeloid Leukemia (the AML PTRC) is a perfect example of that objective. The AML PTRC is adding comprehensive, quantitative proteomic and phosphoproteomic analysis to hundreds of patient samples collected through the Beat AML project, with the accompanying genomic, transcriptomic, and ex vivo drug sensitivity data. The objective is to build a proteomic and/or phosphoproteomic predictor of drug response that performs at least as well as the ex vivo drug sensitivity tests. This general approach is also being applied to understand the biological process of drug resistance with the goal of identifying therapeutic targets that will block the emergence of resistant clones.